Brigatinib

Insights from the world's leading KOLs on the prospects of launched and pipeline therapies for non-small cell lung cancer

Retrieved on: 
Thursday, October 14, 2021
Large-cell lung carcinoma, Amgen, Pharma, Industry, Eli Lilly and Company, Turning Point, Entrectinib, Lists of people executed in the United States, Classification, Daiichi Sankyo, Novartis, Roche, Sanofi, Merck Group, Intelligence, ADC, Brigatinib, NSCLC, Pralsetinib, Medtech, Blueprint, Osimertinib, Chemoradiotherapy, KOL, Research, Turning Point Alcohol and Drug Centre, Alectinib, Mirati, AstraZeneca, Pharmaceutical industry, Fine chemical

A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.

Key Points: 
  • A comprehensive, qualitative review of targeted and novel therapies in the non-small cell lung cancer.
  • In-depth interviews were conducted with 12 of the world's foremost KOLs in the United States and Europe.
  • How do KOLs assess Turning Point's pipeline repotrectinib and AnHeart's taletrectinib in the treatment of ROS1-positive NSCLC?
  • Why do KOLs expect Eli Lilly's late-stage Retevmo/Retsevmo and Blueprint Medicines/Roche's Gavreto will become front-line treatments for RET-fusion positive NSCLC?

ALUNBRIG® (brigatinib) Approved for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Wednesday, June 2, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Lung cancer, Clinical medicine, Health, Branches of biology, Brigatinib, Anaplastic lymphoma kinase, Non-small-cell lung carcinoma, Oncology, Cancer, Small-cell carcinoma, EML4-ALK positive lung cancer, ARIAD Pharmaceuticals, Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Lung cancer, Clinical medicine, Health, Branches of biology, Brigatinib, Anaplastic lymphoma kinase, Non-small-cell lung carcinoma, Oncology, Cancer, Small-cell carcinoma, EML4-ALK positive lung cancer, ARIAD Pharmaceuticals

Onco360, the nations largest independent Oncology Pharmacy, has been selected by Takeda to be a specialty pharmacy partner for ALUNBRIG (brigatinib), an oral therapy option for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

Key Points: 
  • Onco360, the nations largest independent Oncology Pharmacy, has been selected by Takeda to be a specialty pharmacy partner for ALUNBRIG (brigatinib), an oral therapy option for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
  • Onco360 is excited to be become a specialty pharmacy provider for ALUNBRIG patients, said Benito Fernandez, Chief Commercial Officer, Onco360.
  • According to the National Cancer Institutes (NCI) Surveillance, Epidemiology, and End Results (SEER) Program, approximately 235,760 patients will be diagnosed with lung cancer in 2021 with a corresponding 131,880 deaths.
  • When considering all subtypes of lung cancer as well as stages of the disease, lung cancer patients have a poor five-year overall survival (OS) of 21.7%.

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress

Retrieved on: 
Friday, September 18, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Clinical medicine, Medicine, Organic compounds, Tyrosine kinase receptors, Cancer treatments, Lung cancer, Pneumonitis, Interstitial lung disease, Epidermal growth factor receptor, Brigatinib, HER2/neu, Treatment of lung cancer, ALUNBRIG® (brigatinib), ALK+ NSCLC, Mobocertinib (TAK-788), EGFR Exon20 Insertion+ mNSCLC, Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference.
  • Data from the pivotal Phase 2 extension cohort of mobocertinib, EXCLAIM, will read out in fiscal year 2020.
  • In 2019, the U.S. FDA granted mobocertinib Orphan Drug Designation for the treatment of lung cancer with HER2 mutations or EGFR mutations including Exon20 insertion mutations.
  • Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with ALUNBRIG.

Bringing Brigatinib to Neurofibromatosis Type-2 Patients: From Promising Potential to Platform Clinical Trial

Retrieved on: 
Friday, May 29, 2020
Branches of biology, Cytoskeleton, Merlin, Brigatinib, NF2

This alliance across the academic, pharma, and patient landscapes has shortened the time from initial research to active trial, thereby bringing promising treatment options to patients who need them.

Key Points: 
  • This alliance across the academic, pharma, and patient landscapes has shortened the time from initial research to active trial, thereby bringing promising treatment options to patients who need them.
  • This siloed approach to the disease was hampering progress, and all agreed that an "audacious new way" was needed.
  • Leading the INTUITT-NF2 trial are Scott Plotkin, MD, PhD of Massachusetts General Hospital and Jaishri Blakely, MD, of Johns Hopkins University.
  • INTUITT-NF2 will also study multiple drugs over time as they become available (the study is beginning with brigatinib only).

The Lancet Respiratory Medicine Published Study Shows Ensartinib Holds Promise as a New Treatment Option for ALK-positive Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Friday, October 18, 2019
Research, Technology, Clinical trials, Nanotechnology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Chemical compounds, Piperidines, Organic compounds, Lung cancer, Protein kinase inhibitors, Tyrosine kinase receptors, Crizotinib, Pfizer, Anaplastic lymphoma kinase, Non-small-cell lung carcinoma, The Lancet, Brigatinib, Ensartinib, Xcovery

The peer-reviewed manuscript of the study, Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial was published online in The Lancet Respiratory Medicine.

Key Points: 
  • The peer-reviewed manuscript of the study, Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial was published online in The Lancet Respiratory Medicine.
  • The multicenter phase 2 registration study analyzed the efficacy and safety of ensartinib in ALK-positive NSCLC patients that failed prior crizotinib treatment.
  • Ensartinib showed very promising activity in patients with ALK-positive NSCLC whose disease had progressed on previous crizotinib therapy.
  • D. Ross Camidge, M.D., from the University Of Colorado Department Of Medicine provided the Editorial Comment for the Lancet published study.

Alunbrig (Brigatinib; Takeda) Drug Overview & Outlook 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 5, 2019
Pharmaceutical, Health, Oncology, Chemical compounds, Organic compounds, Protein kinase inhibitors, Piperidines, Tyrosine kinase receptors, Lung cancer, Pyrimidines, Brigatinib, ALK inhibitor, Anaplastic lymphoma kinase, Crizotinib, Non-small-cell lung carcinoma

Alunbrig (brigatinib; Takeda) is a dual anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.

Key Points: 
  • Alunbrig (brigatinib; Takeda) is a dual anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.
  • In preclinical studies, Alunbrig showed potent activity against secondary ALK mutations responsible for resistance to first-generation ALK inhibitor Xalkori (crizotinib; Pfizer/Merck KGaA), including the L1196M gatekeeper mutation.
  • While Alunbrig also showed activity against mutated EGFR and its analogous secondary gatekeeper mutation, T790M, the drug is primarily being developed for ALK-positive NSCLC non-small cell lung cancer.
  • Takeda is also currently conducting a Phase III trial of the drug in the first-line setting in an effort to increase Alunbrig's peak market share.

Takeda Presents Results from Lung Portfolio Including Phase 1/2 Study of TAK-788 in a Rare Form of NSCLC and New Data on Overall Health-Related Quality of Life for ALUNBRIG® (brigatinib)

Retrieved on: 
Monday, June 3, 2019
Health, Biotechnology, Clinical trials, Oncology, Pharmaceutical, Chemical compounds, Piperidines, Tyrosine kinase receptors, Brigatinib, Pyrimidines, Takeda Pharmaceutical Company, Anaplastic lymphoma kinase, Non-small-cell lung carcinoma, Organic compounds

These findings build upon our ALTA-1L efficacy data and illustrate ALUNBRIGs potential to provide a meaningful benefit for patients life quality.

Key Points: 
  • These findings build upon our ALTA-1L efficacy data and illustrate ALUNBRIGs potential to provide a meaningful benefit for patients life quality.
  • Results also showed improvements for patients receiving ALUNBRIG across functional scales, with significant improvement seen for physical, emotional and cognitive functions.
  • The safety profile of ALUNBRIG in these subgroups was consistent with what has been reported previously, with no new safety concerns.
  • These findings add to the body of evidence evaluating ALUNBRIG in the first-line setting for patients with ALK+ NSCLC.

Forbius’ AVID100, a Novel Anti-EGFR ADC, Reports Positive Phase 1 Data at AACR: Exceptionally High RP2D Established, Phase 2 in SCCHN and sqNSCLC Ongoing

Retrieved on: 
Friday, March 29, 2019
Health, Biotechnology, Clinical trials, Oncology, Chemical compounds, Epidermal growth factor receptor, Oncogenes, Organic compounds, Quinazolines, Branches of biology, Takeda Pharmaceutical Company, Amines, Brigatinib, Autocrine signaling

An additional AACR poster presentation will feature preclinical data confirming AVID100s novel mechanism of action, which potently targets tumor cells while sparing EGFR-expressing non-tumor cells.

Key Points: 
  • An additional AACR poster presentation will feature preclinical data confirming AVID100s novel mechanism of action, which potently targets tumor cells while sparing EGFR-expressing non-tumor cells.
  • In preclinical studies, AVID100 demonstrated significant anti-cancer activity, including in EGFR-overexpressing tumor models that are resistant to marketed EGFR inhibitors.
  • AVID100 is the only anti-EGFR ADC in clinical development that targets both wild-type and mutant forms of EGFR.
  • Forbius is a clinical-stage protein engineering company that designs and develops novel biologics for the treatment of fibrosis and cancer.